Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2023-09-21 Investor Presentation
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 21, 2023. It reports that Cidara Therapeutics presented at a Research and Development Day via webinar and that the slide presentation is attached as an exhibit. The document does not contain financial statements or detailed financial data but rather announces an event and provides a presentation. The length is 3156 characters, which is relatively short and consistent with an announcement rather than a full report. The content fits the description of an Investor Presentation (IP) as it focuses on a corporate presentation related to research and development. Therefore, the appropriate classification is Investor Presentation (IP).
2023-09-21 English
FORM 4
Director's Dealing
2023-09-13 English
FORM 4
Director's Dealing
2023-09-13 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes a press release about Janssen Pharmaceuticals delivering an Election to Proceed Notice under a license agreement. The document is short (3298 characters) and primarily serves as an announcement of an event rather than a detailed financial report or other specific filing type. It does not contain financial statements, audit information, or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-09-06 English
FORM 4
Director's Dealing
2023-08-15 English
FORM 4
Director's Dealing
2023-08-09 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.